| Business Summary | | Transgenomic,
Inc.
provides
tools
for
the
separation
and
analysis
of
nucleic
acids
to
researchers
seeking
to
discover
and
understand
variations
in
the
human
genetic
code
and
the
relationship
of
these
variations
to
disease.
In
addition,
the
Company's
tools,
such
as
the
WAVE
system,
are
versatile,
and
can
be
used
for
size-based,
double-strand
DNA
separation
and
analysis,
single-strand
DNA
separation
and
analysis
and
DNA
purification. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Transgenomic,
Inc.
develops,
manufactures,
and
sells
research
tools
for
the
life
sciences
industry.
The
tools
enable
researchers
to
discover
and
understand
variations
in
the
human
genetic
code.
For
the
six
months
ended
6/30/01,
net
sales
increased
39%
to
$17.5
million.
Net
loss
fell
55%
to
$2.8
million.
Revenues
reflect
increased
installation
base
of
WAVE
Systems.
Lower
loss
reflects
a
decrease
in
stock-based
compensation
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Collin D' Silva, 44 Chairman,
Pres, CEO | $136K | Gregory Duman, 45 CFO,
Exec. VP of Fin. and Admin., Director | -- | Douglas Gjerde, Ph.D., 48 Director,
CSO | -- | John Doyle, 56 Exec.
VP, Emerging Markets | 155K | Mitchell Murphy, 44 VP,
Sec., Treasurer | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|